8 Protected TCM Varieties Exceeding “RMB 1 Billion”, Which Do You Think is the Next One?

According to Menet’s data statistics of competition pattern of China’s Chinese patent medicine (CPM) market terminal and competition pattern of China’s urban retail pharmacy CPM terminal, there were 21 protected TCM varieties whose sales exceeding RMB 500 million in 2015, of which, the sales of 8 varieties exceed RMB 1 billion.

Table 1: Protected TCM varieties with sales exceeding RMB 500 million in 2015

(Unit: RMB 100 million)

(Data source: CFDA website, Menet database)

Xuesaitong for Injection (lyophilized)

The major sales market of Xuesaitong for Injection (lyophilized) was China’s public medical institution terminal, with the sales of recent three years all exceeding RMB 4 billion every year.

There are two manufacturing enterprises of this product. Harbin Zhenbao Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of ZBD Pharmaceutical, and its Xuesaitong for Injection (lyophilized) has reached about 60% market share in all the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers in recent three years, but its sales slightly declined in 2015, with the growth of -1.19%.

The other manufacturing enterprise is KPC Pharmaceuticals, Inc. Sales of such product of the enterprise rapidly grew in the above four CPM patterns in 2015, exceeding RMB 2 billion, with the growth of 11.38%.

Salvianolate Injection

Salvianolate Injection is an exclusive product of Shanghai Green Valley Pharmaceutical Co., Ltd. The major sales market of the product was China’s public medical institution terminal.

The total sales of this product in the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers have exceeded RMB 4 billion since 2014, but the sales slightly declined in 2015, with the decline of 2.45%.

Salvianolate Injection is a cardiovascular disease drug. It ranked first among the TOP20 products of the cardiovascular disease drug market in the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers in 2015, with the market share of 8.85%.

Naoxintong Capsules

As an exclusive product of Shaanxi Buchang Pharmaceutical Co., Ltd., Naoxintong Capsules had excellent achievements both in China’s public medical institution terminal and China’s urban retail pharmacy terminal.

The total sales of Naoxintong Capsules in the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers exceeded RMB 2.3 billion in 2014, and grew to RMB 2.52 billion in 2015, with the growth of 7.07%.

Sales of Naoxintong Capsules in the CPM pattern of China’s urban retail pharmacies were RMB 470 million in 2015.

Shenqi Fuzheng Injection

Shenqi Fuzheng Injection is an exclusive product of Livzon (Group) Limin Pharmaceutical Factory. The major sales market of the product was public medical institution terminal.

The total sales of Shenqi Fuzheng Injection in the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers have risen steadily in recent three years, and grew to RMB 2.57 billion in 2015, with the growth of 18.82%.

Reduning Injection

Reduning Injection is an exclusive product of Jiangsu Kanion Pharmaceutical Co., Ltd. The major sales market of the product was China’s public medical institution terminal.

The total sales of Reduning Injection in the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers have risen steadily in recent three years, and both the growth in 2014 and 2015 was about 9%.

Lanqin Oral Liquid

As an exclusive product of Yangtze River Pharmaceutical Group Co., Ltd., Lanqin Oral Liquid had excellent achievements both in China’s public medical institution terminal and China’s urban retail pharmacy terminal.

The total sales of Lanqin Oral Liquid in the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers all have exceeded RMB 1 billion in recent three years, but its sales slightly declined in 2015, with the growth of -1.23%.

Sales of Lanqin Oral Liquid in the CPM pattern of China’s urban retail pharmacies were RMB 540 million in 2015.

Tanreqing Injection

Tanreqing Injection is an exclusive product of Shanghai Kaibao Pharmaceutical Co., Ltd. The major sales market of the product was China’s public medical institution terminal.

Both the total sales of Tanreqing Injection in the CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers exceeded RMB 1.7 billion in 2014-2015, but its sales slightly declined in 2015, with the growth of -2.11%.

Shensongyangxin Capsules

As an exclusive product of Beijing Yiling Pharmaceutical Co., Ltd., Shensongyangxin Capsules had excellent achievements both in China’s public medical institution terminal and China’s urban retail pharmacy terminal.

Both the total sales of Shensongyangxin Capsules in the four CPM patterns of China’s urban public hospitals, county public hospitals, urban communities and town health centers exceeded RMB 1 billion in 2014-2015, and its sales in 2015 grew to RMB 1.12 billion, with the growth of 10.82%.

Sales of Shensongyangxin Capsules in the CPM pattern of China’s urban retail pharmacies were RMB 150 million in 2015.

Treasures of China’s TCM

China issued Regulations on Protection of Traditional Chinese Medicines in 1992 to take appropriate protective measures for TCM intellectual property. There have been more than 200 protected TCM varieties, as shown by CFDA website data. According to data statistical results of Menet, and there were more than 70 protected TCM varieties with sales exceeding RMB 100 million in 2015, which are treasures of China’s TCM cause.

Article 43, Chapter VI of Law of the People’s Republic of China on Traditional Chinese Medicine mentions that: Holders of TCM traditional knowledge have the right to inherit and use the TCM traditional knowledge held by them, and the informed consent and benefit sharing rights, etc. for others’ obtaining and use of the TCM traditional knowledge held by them. China implements special protection for the traditional TCM prescription composition and production processes that are identified to be national secrets according to law.

The above TCM Law will be formally implemented from July 1, 2017. (Menet Lu Qimei)